Christina Coleman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christina Coleman has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Hallie Coltin
Department of Pediatric Hematology/Oncology, CHU Sainte Justine, Université de Montréal, Montréal, QC H3C 3A7, Canada
2 shared publications - Abha Anshu Gupta
Division of Haematology/Oncology Princess Margaret Cancer Center, The Hospital for Sick Children Toronto Ontario Canada
1 shared publication - Akanksha Senapati
Children’s Brain Tumour Research Network (CBTRN), Royal Manchester Children’s Hospital, Oxford Road, Manchester University NHS Foundation Trust, England, UK
1 shared publication - Chantel Cacciotti
Children’s Hospital London Health Sciences/Western University, London, Ontario, Canada
1 shared publication - Dardye Eugène
Division of Pediatric Endocrinology, CHUL-Laval, Quebec City, QC G1V 0A6, Canada
1 shared publication - Eric Bouffet
Division of Haematology/Oncology Hospital for Sick Children Toronto Ontario Canada
1 shared publication
Latest Publications
- 19 January 2026
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 176 (3) , 172
High-dose chemotherapy and craniospinal irradiation-sparing approach for WNT medulloblastoma of early childhood
- 19 January 2026
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 176 (3) , 172
High-dose chemotherapy and craniospinal irradiation-sparing approach for WNT medulloblastoma of early childhood
- Open Access
Significant Response to Denosumab Yet with Severe Rebound Hypercalcemia in a 9-Year-Old Boy with Aneurysmal Bone Cyst: A Case Report
A 9-year-old boy presented with edema of the left cheek. He was diagnosed with a large aneurysmal bone cyst of the mandibular bone. Off-label treatment with denosumab for 17 months resulted in a significant reduction in the lesion. Five months after discontinuing denosumab, the patient developed severe rebound hypercalcemia and acute kidney injury, which resolved with corticosteroids. Two years after treatment discontinuation, the lesion continues to decrease in size. This case highlights the efficacy of denosumab as an off-label treatment for aneurysmal bone cysts, though it can be associated with hypercalcemia and acute kidney injury. We conclude that the use of denosumab should be considered on a case-by-case basis, with regular monitoring for side effects.
Open AccessSignificant Response to Denosumab Yet with Severe Rebound Hypercalcemia in a 9-Year-Old Boy with Aneurysmal Bone Cyst: A Case Report
A 9-year-old boy presented with edema of the left cheek. He was diagnosed with a large aneurysmal bone cyst of the mandibular bone. Off-label treatment with denosumab for 17 months resulted in a significant reduction in the lesion. Five months after discontinuing denosumab, the patient developed severe rebound hypercalcemia and acute kidney injury, which resolved with corticosteroids. Two years after treatment discontinuation, the lesion continues to decrease in size. This case highlights the efficacy of denosumab as an off-label treatment for aneurysmal bone cysts, though it can be associated with hypercalcemia and acute kidney injury. We conclude that the use of denosumab should be considered on a case-by-case basis, with regular monitoring for side effects.
- Open Access
- 15 May 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (5) , 281
Approaches to Reduce Toxicity in Pediatric Brain Tumors
Pediatric central nervous system (CNS) tumor survivors are highly susceptible to long-term toxicity due to tumor location and also the treatment received. Advancements in treatment techniques, risk-adapted approaches to therapy with adjustments to treatment regimens—including de-escalation when feasible—along with the addition of supportive therapy and surveillance in these survivors, serve to minimize and manage late effects of therapy.
- 15 May 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (5) , 281
Open AccessApproaches to Reduce Toxicity in Pediatric Brain Tumors
Pediatric central nervous system (CNS) tumor survivors are highly susceptible to long-term toxicity due to tumor location and also the treatment received. Advancements in treatment techniques, risk-adapted approaches to therapy with adjustments to treatment regimens—including de-escalation when feasible—along with the addition of supportive therapy and surveillance in these survivors, serve to minimize and manage late effects of therapy.